<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Geriatr Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Int J Geriatr Psychiatry</journal-id><journal-id journal-id-type="publisher-id">gps</journal-id><journal-title-group><journal-title>International Journal of Geriatric Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0885-6230</issn><issn pub-type="epub">1099-1166</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24644106</article-id><article-id pub-id-type="pmc">4285965</article-id><article-id pub-id-type="doi">10.1002/gps.4088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alaka</surname><given-names>Karla J</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noble</surname><given-names>William</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Montejo</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="au3">3</xref><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Due&#x000f1;as</surname><given-names>H&#x000e9;ctor</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Munshi</surname><given-names>Autar</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Strawn</surname><given-names>Jeffrey R</given-names></name><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lenox-Smith</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahl</surname><given-names>Jonna</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bidzan</surname><given-names>Leszek</given-names></name><xref ref-type="aff" rid="au7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dorn</surname><given-names>Brita</given-names></name><xref ref-type="aff" rid="au8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ball</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au9">9</xref></contrib><aff id="au1"><label>1</label><institution>Eli Lilly and Company</institution><addr-line>Indianapolis, IN, USA</addr-line></aff><aff id="au2"><label>2</label><institution>inVentiv Health Clinical</institution><addr-line>Burlington, MA, USA</addr-line></aff><aff id="au3"><label>3</label><institution>Universidad de Salamanca</institution><addr-line>Salamanca, Spain</addr-line></aff><aff id="au4"><label>4</label><institution>Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de Salamanca</institution><addr-line>Salamanca, Spain</addr-line></aff><aff id="au5"><label>5</label><addr-line>Sydney, Nova Scotia, Canada</addr-line></aff><aff id="au6"><label>6</label><institution>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine</institution><addr-line>Cincinnati, OH, USA</addr-line></aff><aff id="au7"><label>7</label><institution>Medical University of Gdansk</institution><addr-line>Gdansk, Poland</addr-line></aff><aff id="au8"><label>8</label><addr-line>Berlin, Germany</addr-line></aff><aff id="au9"><label>9</label><institution>Indiana University School of Medicine</institution><addr-line>Indianapolis, IN, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence to:</italic> K. J. Alaka, E-mail: <email>alaka_karla_j@lilly.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>20</day><month>2</month><year>2014</year></pub-date><volume>29</volume><issue>9</issue><fpage>978</fpage><lpage>986</lpage><history><date date-type="received"><day>09</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors. <italic>International Journal of Geriatric Psychiatry</italic> published by John Wiley &#x00026; Sons, Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><sec><title>Objective</title><p>This was a flexible-dosed study to evaluate the efficacy and safety of duloxetine 30&#x02013;120&#x000a0;mg once daily in the treatment of generalized anxiety disorder (GAD) in older adult patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients with GAD, who were at least 65&#x000a0;years of age, were randomly assigned to double-blind treatment with either duloxetine (<italic>N</italic>&#x000a0;=&#x000a0;151) or placebo (<italic>N</italic>&#x000a0;=&#x000a0;140). The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) total score, and the primary endpoint was at week 10. Global functioning was assessed by the Sheehan Disability Scale (SDS). Safety and tolerability was assessed by the occurrence of treatment-emergent adverse events, serious adverse events, laboratory analyses, and vital signs. Analyses were conducted on an intent-to-treat basis.</p></sec><sec><title>Results</title><p>The overall baseline mean HAM-A total score was 24, and SDS global score was 14. Completion rates were 75% for placebo and 76% for duloxetine. At week 10, duloxetine was superior to placebo on mean changes from baseline in HAM-A total scores (&#x02212;15.9 <italic>vs</italic>. &#x02212;11.7, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and in SDS global scores (&#x02212;8.6 <italic>vs</italic>. &#x02212;5.4, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Treatment-emergent adverse events occurred in &#x02265;5% of duloxetine-treated patients and twice the rate than with placebo including constipation (9% <italic>vs</italic>. 4%, <italic>p</italic>&#x000a0;=&#x000a0;0.06), dry mouth (7% <italic>vs</italic>. 1%, <italic>p</italic>&#x000a0;=&#x000a0;0.02), and somnolence (6% <italic>vs</italic>. 2%, <italic>p</italic>&#x000a0;=&#x000a0;0.14).</p></sec><sec><title>Conclusion</title><p>Duloxetine treatment was efficacious in the improvement of anxiety and functioning in older adult patients with GAD, and the safety profile was consistent with previous GAD studies. &#x000a9; 2014 The Authors. <italic>International Journal of Geriatric Psychiatry</italic> published by John Wiley &#x00026; Sons, Ltd.</p></sec><sec><title>Key points</title><list list-type="bullet"><list-item><p>Treatment with duloxetine <italic>versus</italic> placebo can significantly reduce symptoms of generalized anxiety disorder and was associated with improved global function and increased enjoyment and satisfaction with life in patients 65&#x000a0;years and older.</p></list-item><list-item><p>The safety and tolerability profile for duloxetine in this older adult patient population was consistent with the established profile for treatment of generalized anxiety disorder in the broader mostly younger (&#x02265;18&#x000a0;years of age) population, and there were no new safety findings.</p></list-item></list></sec></abstract><kwd-group><kwd>anxiety</kwd><kwd>functioning</kwd><kwd>duloxetine</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Generalized anxiety disorder (GAD) is a chronic disabling condition characterized by persistent, excessive, and difficult-to-control worry (<xref rid="b43" ref-type="bibr">Wittchen <italic>et al</italic>., 2002</xref>). GAD typically onsets in young adulthood but is also known to onset later in life (<xref rid="b24" ref-type="bibr">Le Roux <italic>et al</italic>., 2005</xref>). In the National Comorbidity Replication Survey, GAD had a prevalence rate of nearly 12% in 2575 adults over the age of 55&#x000a0;years (<xref rid="b7" ref-type="bibr">Byers <italic>et al</italic>., 2010</xref>). A recent review of epidemiological data from European studies reported an estimated prevalence rate of 3.4% for GAD in persons &#x0003e;65&#x000a0;years of age (<xref rid="b44" ref-type="bibr">Wittchen <italic>et al</italic>., 2011</xref>).</p><p>Considering the neurobiology of GAD, pharmacological guidelines recommend treatment with selective serotonin reuptake inhibitors, selective serotonin&#x02013;norepinephrine reuptake inhibitors, or pregablin (<xref rid="b29" ref-type="bibr">Montgomery <italic>et al</italic>., 2006</xref>; <xref rid="b21" ref-type="bibr">Hoffman and Mathew, 2008</xref>; <xref rid="b5" ref-type="bibr">Baldwin <italic>et al</italic>., 2012</xref>; <xref rid="b6" ref-type="bibr">Bandelow <italic>et al</italic>., 2012</xref>). Approved selective serotonin reuptake inhibitors for GAD include escitalopram (<xref rid="b10" ref-type="bibr">Davidson <italic>et al</italic>., 2004</xref>; <xref rid="b3" ref-type="bibr">Allgulander <italic>et al</italic>., 2006</xref>; <xref rid="b25" ref-type="bibr">Lenze <italic>et al</italic>., 2009</xref>) and paroxetine (<xref rid="b31" ref-type="bibr">Pollack <italic>et al</italic>., 2001</xref>; <xref rid="b36" ref-type="bibr">Rickels <italic>et al</italic>., 2003</xref>; <xref rid="b42" ref-type="bibr">Stocchi <italic>et al</italic>., 2003</xref>). Approved serotonin&#x02013;norepinephrine reuptake inhibitors include duloxetine (<xref rid="b20" ref-type="bibr">Hartford <italic>et al</italic>., 2007</xref>; <xref rid="b23" ref-type="bibr">Koponen <italic>et al</italic>., 2007</xref>; <xref rid="b38" ref-type="bibr">Rynn <italic>et al</italic>., 2008</xref>; <xref rid="b30" ref-type="bibr">Nicolini <italic>et al</italic>., 2009</xref>) and venlafaxine (<xref rid="b9" ref-type="bibr">Davidson <italic>et al</italic>., 1999</xref>; <xref rid="b15" ref-type="bibr">Gelenberg <italic>et al</italic>., 2000</xref>; <xref rid="b35" ref-type="bibr">Rickels <italic>et al</italic>., 2000</xref>; <xref rid="b2" ref-type="bibr">Allgulander <italic>et al</italic>., 2001</xref>; <xref rid="b22" ref-type="bibr">Katz <italic>et al</italic>., 2002</xref>). A meta-analysis of 14 pharmacological treatment studies for GAD in older adults found an overall odds ratio (OR) of 0.32 favoring active treatment, with an OR of 0.19 for benzodiazepine treatments compared with OR of 0.46 for antidepressants (<xref rid="b16" ref-type="bibr">Gon&#x000e7;alves and Byrne, 2012</xref>).</p><p>Supportive data on the efficacy and safety of duloxetine in the treatment of older patients (&#x02265;65&#x000a0;years old) with GAD were provided from an analysis of 73 patients from four acute therapy, placebo-controlled trials (duloxetine <italic>n</italic>&#x000a0;=&#x000a0;45, placebo <italic>n</italic>&#x000a0;=&#x000a0;28) (<xref rid="b11" ref-type="bibr">Davidson <italic>et al</italic>., 2008</xref>). Given the relatively small sample size in that analysis, this clinical trial was undertaken to further evaluate the efficacy and safety of duloxetine in the treatment of patients with GAD, who were &#x02265;65&#x000a0;years of age.</p></sec><sec sec-type="methods"><title>Methods</title><p>This phase IV study was conducted under protocol F1J-MC-HMGF (ClinicalTrials.gov identifier: NCT01118780) in 47 sites across nine countries: Argentina, Austria, Canada, Germany, Mexico, Poland, Spain, the UK, and the USA. Enrollment began in October 2010, and the study was completed in July 2012. Institutional review boards at each site approved the protocol, which was developed in accordance with the ethical guidelines of Good Clinical Practice and the Declaration of Helsinki. All patients provided written consent after the study was explained, their questions answered, and before any study procedures were initiated.</p><p>Male and female outpatients aged &#x02265;65&#x000a0;years were eligible for study entry if they met criteria for GAD (DSM-IV TR) (<xref rid="b4" ref-type="bibr">APA, 1994</xref>) defined by the Mini International Neuropsychiatric Interview (<xref rid="b41" ref-type="bibr">Sheehan <italic>et al</italic>., 1998</xref>) and had at least moderately severe symptoms as indicated by a Clinical Global Impressions (CGI) of Severity of Illness (<xref rid="b17" ref-type="bibr">Guy, 1976</xref>) score of &#x02265;4, Covi Anxiety Scale (CAS) (<xref rid="b26" ref-type="bibr">Lipman, 1982</xref>) score of &#x02265;9, no item score of &#x0003e;3 on the Raskin Depression Scale (RDS) (<xref rid="b33" ref-type="bibr">Raskin <italic>et al</italic>., 1969</xref>), the CAS total score had to be greater than the RDS total score, and a Hospital Anxiety and Depression Scale (HADS) (<xref rid="b45" ref-type="bibr">Zigmond and Snaith, 1983</xref>) anxiety subscale score of &#x02265;10. Stable medical comorbidities that did not pose a safety risk as determined by physical examination, electrocardiogram (ECG), and laboratory results were allowed. Patients were required to have a level of understanding that allowed them to communicate intelligibly and a Mini mental state examination (<xref rid="b14" ref-type="bibr">Folstein <italic>et al</italic>., 1975</xref>) score of &#x02265;24.</p><p>Patients were excluded if they met criteria for any DSM-IV TR Axis I diagnosis other than GAD, with the exception of comorbid social/specific phobia, or any DSM-IV TR Axis II disorder that would impair study compliance, benzodiazepine use in the prior 14&#x000a0;days, judged clinically to be at serious risk of harm to self or others, history of alcohol or any psychoactive substance abuse or dependence (DSM-IV TR definition) within the past 6&#x000a0;months, positive urine screen for any substances of abuse, excessive use of caffeine, taken any excluded medication with central nervous system activity in the prior 7&#x000a0;days, treatment with monoamine oxidase inhibitor (MAOI) or fluoxetine within the prior 30&#x000a0;days or may need to use an MAOI during the study or within 5&#x000a0;days of discontinuation of study drug, and judged to be a poor medical or psychiatric risk for study compliance in the opinion of the investigator.</p><sec><title>Study design</title><p>This was a randomized, double-blind, placebo-controlled, flexible-dose, parallel group trial that consisted of three study periods: screening/washout period (up to 30&#x000a0;days), 10-week therapy period, and a 2-week taper-off drug period. Study visits were conducted at weeks 2, 4, 7, and 10.</p><p>Eligible patients were randomly assigned (1&#x000a0;:&#x000a0;1) to treatment with oral duloxetine or placebo once daily (QD) <italic>via</italic> computer-generated random sequence using an interactive voice response system. Patients assigned to receive duloxetine initiated treatment with 30&#x000a0;mg QD for 2&#x000a0;weeks; then, the dose was increased to 60&#x000a0;mg QD based on investigator decision to maximize efficacy or if the CGI&#x02013;Improvement (CGI-I) Scale (<xref rid="b17" ref-type="bibr">Guy, 1976</xref>) score was &#x02265;3. Dose escalation was allowed only at scheduled visits if the patient was adequately tolerating the current dose. Dose increases were from 60 to 90&#x000a0;mg and from 90 to 120&#x000a0;mg QD. If the increased dose was not tolerated at any time, patients were returned to their previous dose, and patients were not allowed any additional dose changes for the remainder of the study. All patients were required to maintain a minimum dose of 30&#x000a0;mg to remain in the treatment phase of the study. Patients were required to undergo the double-blind drug-taper phase, unless the patient planned to start active treatment immediately upon completion of the study. During the drug-taper phase, patients on duloxetine 60&#x000a0;mg received 30&#x000a0;mg QD for 1&#x000a0;week followed by placebo for the second week. Patients taking duloxetine 90 or 120&#x000a0;mg received 60&#x000a0;mg QD for 1&#x000a0;week then 30&#x000a0;mg QD for the second week. Patients on duloxetine 30&#x000a0;mg QD or on placebo received placebo for both weeks.</p></sec><sec><title>Efficacy measures</title><p>The primary efficacy measure was Hamilton Anxiety Rating Scale (HAM-A) (<xref rid="b18" ref-type="bibr">Hamilton, 1959</xref>) total score. The HAM-A was chosen to assess anxiety because it is commonly used in pharmacological trials and was used in the four previous studies of duloxetine in GAD. HAM-A was administered at each visit and at the primary endpoint: week 10. The structured interview guide for HAM-A (<xref rid="b39" ref-type="bibr">Shear <italic>et al</italic>., 2001</xref>) was used to collect HAM-A data. Response was defined as a 50% reduction from baseline in the HAM-A total score (<xref rid="b1" ref-type="bibr">Allgulander <italic>et al</italic>., 2008</xref>), and remission was defined as a HAM-A total score of &#x02264;7 (<xref rid="b12" ref-type="bibr">Doyle and Pollack, 2003</xref>).</p><p>The key secondary efficacy measure was the Sheehan Disability Scale (<xref rid="b40" ref-type="bibr">Sheehan <italic>et al</italic>., 1996</xref>) for global functioning that rates impairment in three life domains: work, social, and family/home management. Other secondary efficacy measures included the HAM-A psychic anxiety factor (sum of items assessing anxious mood, tension, fears, insomnia, concentration, depressed mood, and behavior at interview), HAM-A somatic anxiety factor (sum of items assessing somatic muscular, somatic sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, and autonomic symptoms), HAM-A individual items for anxious mood and tension, and the HADS anxiety and depression subscales. Additional secondary outcomes included symptom improvement assessed by the CGI-I and by patients using the self-rating Patient Global Impression of Improvement Scale (<xref rid="b17" ref-type="bibr">Guy, 1976</xref>). Quality of life was assessed by the 16-item Quality of Life Enjoyment and Satisfaction Questionnaire&#x02013;Short Form (<xref rid="b13" ref-type="bibr">Endicott <italic>et al</italic>., 1993</xref>). In addition, patients were also assessed for the presence, severity, and interference of pain symptoms using the self-assessment Brief Pain Inventory (<xref rid="b8" ref-type="bibr">Cleeland and Ryan, 1994</xref>).</p></sec><sec><title>Safety and tolerability</title><p>Safety and tolerability was assessed through collection and monitoring discontinuation rates, treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), vital signs, laboratory analyses, and ECGs. In addition, a solicited assessment of the occurrence of any falls and the circumstances/consequences associated with any fall was made at every visit. Solicited questioning of suicide-related behavior and ideations was also completed at every visit using the Columbia Suicide Severity Rating Scale (<xref rid="b32" ref-type="bibr">Posner <italic>et al</italic>., 2011</xref>).</p></sec><sec><title>Statistical analysis</title><p>Approximately 288 patients were to be randomly assigned to receive either duloxetine or placebo treatment in a 1&#x000a0;:&#x000a0;1 ratio that would provide approximately 80% power to detect a 0.35 effect size relative to placebo in the baseline-to-endpoint mean change on the HAM-A total score. The effect size was based on HAM-A total score data collected from older patients, who participated in four placebo-controlled studies of duloxetine in GAD, and the pooled analysis effect size was 0.40. The sample size was determined using a two-sided test with <italic>p</italic>&#x000a0;=&#x000a0;0.05 and assumed that 10% of the patients would discontinue by week 2 without providing postbaseline HAM-A data (<xref rid="b20" ref-type="bibr">Hartford <italic>et al</italic>., 2007</xref>; <xref rid="b23" ref-type="bibr">Koponen <italic>et al</italic>., 2007</xref>; <xref rid="b38" ref-type="bibr">Rynn <italic>et al</italic>., 2008</xref>; <xref rid="b30" ref-type="bibr">Nicolini <italic>et al</italic>., 2009</xref>).</p><p>All analyses were conducted on an intent-to-treat basis. Mean changes from baseline were analyzed using a restricted maximum likelihood-based repeated measures analysis using all postbaseline observations. The model included the fixed categorical effects of treatment, investigator, age, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline score and baseline-by-visit interaction. An unstructured covariance structure was used to model the within-patient errors. The Kenward&#x02013;Rogers method was used to estimate denominator degrees of freedom. Type III sum of squares for the least squares mean was used. Analyses were implemented using <sc>sas</sc> (version 9.1). When analyzing efficacy variables using the repeated measures analysis, the treatment group contrast at the last visit of the double-blind acute therapy phase (week 10) was the primary comparison, and those at earlier postbaseline visits were secondary. In addition, treatment-by-investigator interaction was investigated by adding a treatment-by-investigator interaction term to the model described previously.</p><p>Treatment group differences were evaluated on the basis of a two-sided significance level of 0.05. No adjustments for multiple comparisons were made. Unless otherwise specified, the analysis of variance model used to analyze demographic, efficacy, or safety variables contained the main effects of treatment and investigator. The corresponding analysis of covariance models also included baseline as a continuous covariate and age group as a categorical covariate. Type III sum of squares for the least squares mean was used for the statistical comparison using analysis of variance or analysis of covariance. Unless otherwise specified, in all double-blind analyses, &#x0201c;baseline&#x0201d; refers to the last nonmissing observation at or before the randomization visit, and &#x0201c;endpoint&#x0201d; refers to the last nonmissing observation at or before week 10.</p><p>Categorical comparisons between treatment groups were performed using a Cochran&#x02013;Mantel&#x02013;Haenszel test controlling for pooled investigative site and Fisher's exact test, where appropriate, or Pearson's chi-square test.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patients</title><p>Figure <xref ref-type="fig" rid="fig01">1</xref> shows the number of patients across the stages of recruitment and study participation. Patient demographics and baseline illness severity are summarized in Table <xref ref-type="table" rid="tbl1">1</xref>. The treatment groups did not differ significantly in any characteristic or severity of illness at baseline. Overall, 83.2% of patients had one or more preexisting stable medical condition, the most common of which was hypertension (44.0%), and 81.8% of patients used concomitant medications. One hundred fifteen (76.2%) duloxetine-treated patients and 105 (75.0%) placebo-treated patients completed the study (Figure <xref ref-type="fig" rid="fig01">1</xref>). There were no significant differences between duloxetine and placebo treatment groups on rates of discontinuation because of adverse events (9.9% <italic>vs</italic>. 10.7%, respectively; <italic>p</italic>&#x000a0;=&#x000a0;0.85).</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Consort diagram of recruitment and patient flow through the study.</p></caption><graphic xlink:href="gps0029-0978-f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Baseline characteristics and illness severity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">Duloxetine</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;140</th><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;151</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD) years</td><td align="char" char="." rowspan="1" colspan="1">71.7 (5.0)</td><td align="char" char="." rowspan="1" colspan="1">71.4 (5.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic>n</italic> (%)</td><td align="char" char="." rowspan="1" colspan="1">112 (80.0)</td><td align="char" char="." rowspan="1" colspan="1">114 (75.5)</td></tr><tr><td align="left" colspan="3" rowspan="1">Ethnicity<xref ref-type="table-fn" rid="tfn1-1">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">African descent, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">5 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian, <italic>n</italic> (%)</td><td align="char" char="." rowspan="1" colspan="1">120 (85.7)</td><td align="char" char="." rowspan="1" colspan="1">129 (85.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Native American, <italic>n</italic> (%)</td><td align="char" char="." rowspan="1" colspan="1">18 (12.9)</td><td align="char" char="." rowspan="1" colspan="1">17 (11.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE total score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">28.5 (1.7)</td><td align="char" char="." rowspan="1" colspan="1">28.4 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">CGI-S, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">4.4 (0.6)</td><td align="char" char="." rowspan="1" colspan="1">4.4 (0.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A total score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">24.4 (7.1)</td><td align="char" char="." rowspan="1" colspan="1">24.6 (6.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A Psychic Anxiety Factor score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">13.4 (3.4)</td><td align="char" char="." rowspan="1" colspan="1">13.6 (3.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A Somatic Anxiety Factor score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">10.9 (4.8)</td><td align="char" char="." rowspan="1" colspan="1">11.0 (4.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">HADS Anxiety subscale score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">13.6 (3.3)</td><td align="char" char="." rowspan="1" colspan="1">13.9 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">HADS Depression subscale, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">7.4 (4.3)</td><td align="char" char="." rowspan="1" colspan="1">7.4 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">SDS Global Functional Impairment score, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">14.2 (7.5)</td><td align="char" char="." rowspan="1" colspan="1">13.7 (7.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q-LES-Q-SF, mean % of maximum score (SD)</td><td align="char" char="." rowspan="1" colspan="1">49.3 (14.6)</td><td align="char" char="." rowspan="1" colspan="1">49.0 (14.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BPI 24-h Average Pain Severity, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">3.2 (2.6)</td><td align="char" char="." rowspan="1" colspan="1">3.1 (2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">BPI Pain Interference, mean (SD)</td><td align="char" char="." rowspan="1" colspan="1">3.0 (2.4)</td><td align="char" char="." rowspan="1" colspan="1">2.8 (2.3)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p>SD, standard deviation; BPI, Brief Pain Inventory; CGI-S, Clinical Global Impressions&#x02013;Severity of Illness; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; MMSE, Mini mental state examination; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire&#x02013;Short Form; SDS, Sheehan Disability Scale.</p></fn><fn id="tfn2"><p>There were no significance between treatment group differences in any of the baseline variables.</p></fn><fn id="tfn1-1"><label>a</label><p>Two patients in the placebo group (1.4%) did not report ethnicity/race information.</p></fn></table-wrap-foot></table-wrap><p>Over the course of the study, 48 (31.8%) patients in the duloxetine arm did not have a dose escalation and remained on 30&#x000a0;mg, 52 (34.4%) had one escalation to 60&#x000a0;mg, 36 (23.8%) had two escalations to 90&#x000a0;mg, and 15 (9.9%) had three escalations to 120&#x000a0;mg. In the placebo arm, 31 (22.1%) of patients did not have a dose increase, 44 (31.4%) had one escalation, 28 (20.0%) had two escalations, and 37 (26.4%) had three escalations. Between-treatment differences in dose escalations were not significant.</p></sec><sec><title>Efficacy</title><p>Patients treated with duloxetine <italic>versus</italic> placebo had significantly greater baseline-to-endpoint improvement on the primary efficacy measure, the HAM-A total score (&#x02212;15.9 <italic>vs</italic>. &#x02212;11.7, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) (Table <xref ref-type="table" rid="tbl2">2</xref>). Significance between treatment group differences began as early as week 4 and continued to study end at week 10 (Figure <xref ref-type="fig" rid="fig02">2</xref>). Treatment with duloxetine <italic>versus</italic> placebo was also associated with significantly greater improvement in other measures of anxiety, depression, quality of life, and overall functioning (Table <xref ref-type="table" rid="tbl2">2</xref>). Significant improvement in global functioning, social/leisure activities, and in family/home management began at week 4 of treatment with duloxetine, which was sustained to study end. (Figure <xref ref-type="fig" rid="fig03">3</xref>). Improvement in function for working separated from placebo at week 4 and at endpoint.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Least squares mean changes on efficacy measures and least squares mean endpoint improvement scores in patients treated with duloxetine or placebo</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Scale</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">Duloxetine</th><th align="center" rowspan="2" colspan="1"><italic>p</italic>-value</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;140</th><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;151</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Changes from baseline to endpoint, least squares mean (SE)</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A total score</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;11.7 (0.7)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;15.9 (0.6)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A Psychic Anxiety Factor score</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;6.2 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;8.6 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HAM-A Somatic Anxiety Factor score</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.6 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;7.3 (0.3)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HADS Anxiety</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.6 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;7.8 (0.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HADS Depression</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.6 (0.3)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;3.3 (0.3)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SDS Global Functional Impairment</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;5.4 (0.6)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;8.6 (0.6)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Q-LES-Q-SF</td><td align="char" char="." rowspan="1" colspan="1">9.4 (1.5)</td><td align="char" char="." rowspan="1" colspan="1">15.1 (1.5)</td><td align="char" char="." rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">BPI 24-h Average Pain Severity</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.6 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.1 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">BPI Pain Interference</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;0.7 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;1.2 (0.2)</td><td align="char" char="." rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" colspan="4" rowspan="1">Scores at endpoint, mean (SD)</td></tr><tr><td align="left" rowspan="1" colspan="1">CGI-I</td><td align="char" char="." rowspan="1" colspan="1">2.8 (1.3)</td><td align="char" char="." rowspan="1" colspan="1">2.3 (1.1)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PGI-I</td><td align="char" char="." rowspan="1" colspan="1">3.1 (1.4)</td><td align="char" char="." rowspan="1" colspan="1">2.5 (1.2)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn4"><p>SE, standard error; BPI, Brief Pain Inventory; CGI-I, Clinical Global Impressions&#x02013;Improvement; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; PGI-I, Patient Global Impression of Improvement; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire&#x02013;Short Form; SDS, Sheehan Disability Scale.</p></fn></table-wrap-foot></table-wrap><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Least squares mean change from baseline to endpoint in HAM-A total score (MMRM analysis).</p></caption><graphic xlink:href="gps0029-0978-f2"/></fig><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Least squares mean change from baseline to endpoint on the Sheehan Disability Scale items and Global Functioning Impairment scores (MMRM analysis).</p></caption><graphic xlink:href="gps0029-0978-f3"/></fig><p>Significantly, more patients treated with duloxetine <italic>versus</italic> placebo were perceived to be much improved with CGI-I scores of &#x02264;2 (62.9% <italic>vs</italic>. 45.0%, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In addition, response rates were significantly higher in the duloxetine treatment group as compared with placebo (71.3% <italic>vs</italic>. 45.5%; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) as were rates of remission (44.8% <italic>vs</italic>. 29.5%, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). At study end, significantly more duloxetine-treated <italic>versus</italic> placebo-treated patients (74.6% <italic>vs</italic>. 55.6%, <italic>p</italic>&#x000a0;=&#x000a0;0.001) had sustained improvement, defined as at least 30% reduction in HAM-A total scores at each visit from onset.</p></sec><sec><title>Safety and tolerability</title><p>Treatment-emergent adverse events that occurred in &#x02265;5% of patients treated with duloxetine are summarized in Table <xref ref-type="table" rid="tbl3">3</xref>. Dry mouth, constipation, and somnolence occurred at twice the rate as with placebo, and dry mouth frequency was significantly higher in the duloxetine group. On the basis of the solicited assessment of falls, four (3.5%) placebo-treated patients and five (4.4%) of duloxetine-treated patients (<italic>p</italic>&#x000a0;=&#x000a0;0.75) reported a fall. Each fall incident was cross-checked with vital sign measurements, and no corresponding episodes of treatment-emergent orthostatic hypotension were identified. Treatment-emergent suicidal ideation assessed by the Columbia Suicide Severity Rating Scale was reported for nine patients, five (3.8%) treated with placebo and four (2.8%, <italic>p</italic>&#x000a0;=&#x000a0;0.74) treated with duloxetine, and there were no attempted suicides.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Treatment-emergent adverse events with &#x02265;5% incidence rate for patients treated with duloxetine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Event, <italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1">Placebo</th><th align="left" rowspan="1" colspan="1">Duloxetine</th><th align="left" rowspan="2" colspan="1"><italic>p</italic>-value</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;140</th><th align="center" rowspan="1" colspan="1"><italic>N</italic>&#x000a0;=&#x000a0;151</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any event</td><td align="char" char="." rowspan="1" colspan="1">71 (50.7)</td><td align="char" char="." rowspan="1" colspan="1">91 (60.3)</td><td align="char" char="." rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="char" char="." rowspan="1" colspan="1">9 (6.4)</td><td align="char" char="." rowspan="1" colspan="1">17 (11.3)</td><td align="char" char="." rowspan="1" colspan="1">0.157</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="char" char="." rowspan="1" colspan="1">9 (6.4)</td><td align="char" char="." rowspan="1" colspan="1">16 (10.6)</td><td align="char" char="." rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="char" char="." rowspan="1" colspan="1">5 (3.6)</td><td align="char" char="." rowspan="1" colspan="1">14 (9.3)</td><td align="char" char="." rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="char" char="." rowspan="1" colspan="1">10 (7.1)</td><td align="char" char="." rowspan="1" colspan="1">12 (7.9)</td><td align="char" char="." rowspan="1" colspan="1">0.828</td></tr><tr><td align="left" rowspan="1" colspan="1">Dry mouth</td><td align="char" char="." rowspan="1" colspan="1">2 (1.4)</td><td align="char" char="." rowspan="1" colspan="1">11 (7.3)</td><td align="char" char="." rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">Somnolence</td><td align="char" char="." rowspan="1" colspan="1">3 (2.1)</td><td align="char" char="." rowspan="1" colspan="1">9 (6.0)</td><td align="char" char="." rowspan="1" colspan="1">0.141</td></tr></tbody></table></table-wrap><p>Three SAEs occurred in the duloxetine group. One patient hospitalized approximately 2&#x000a0;months after initiating treatment was diagnosed with angina pectoris, recovered from the event, and completed the study. Another patient with preexisting cardiovascular disease was hospitalized after 6&#x000a0;days of treatment and diagnosed with hypertensive crisis, recovered, then was discontinued from the trial. A third patient hospitalized because of diarrhea following 68&#x000a0;days of treatment was diagnosed with a large intestinal obstruction and died of complications. These events were not considered by the study investigators to be associated with duloxetine treatment or because of any protocol procedure. There were no SAEs reported in the placebo group, and between-treatment differences were not significant (<italic>p</italic>&#x000a0;=&#x000a0;0.25).</p><p>The incidence of abnormal laboratory parameters during the study was not statistically significantly different between treatment groups for any laboratory value. At study endpoint, six duloxetine-treated patients (4.4%) had elevated aspartate aminotransferase/serum glutamic oxaloacetic transaminase levels, which was statistically significantly greater than placebo (0%, <italic>p</italic>&#x000a0;=&#x000a0;0.033). Overall, the mean level of aspartate aminotransferase/serum glutamic oxaloacetic transaminase elevation was less than two times the upper limit of normal, and there were no other related laboratory elevations. However, one duloxetine-treated patient, who was HBcAb IgM-positive, had mildly elevated alanine transaminase at baseline (54&#x000a0;IU/L), levels &#x02265;3&#x000a0;&#x000d7;&#x000a0;upper limit of normal at multiple time points, which subsequently declined while still on duloxetine treatment, and was largely normalized at poststudy follow-up.</p><p>The treatment groups did not significantly differ in mean baseline-to-endpoint changes in sitting systolic blood pressure, orthostatic vital signs, ECG parameters, or in weight, but there were statistically significant duloxetine/placebo treatment differences in sitting diastolic blood pressure (0.3 <italic>vs</italic>. &#x02212;1.7&#x000a0;mmHg; <italic>p</italic>&#x000a0;=&#x000a0;0.020) and sitting pulse rate (1.8 <italic>vs</italic>. &#x02212;1.3&#x000a0;bpm; <italic>p</italic>&#x000a0;=&#x000a0;0.003). These differences were not considered clinically significant.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This was the first multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and tolerability of duloxetine in older patients with GAD. The results show that patients flexibly dosed with duloxetine 30&#x02013;120&#x000a0;mg QD <italic>versus</italic> placebo had significantly reduced anxiety symptoms at 4&#x000a0;weeks, 7&#x000a0;weeks, and at the 10-week endpoint. The lack of separation from placebo at the week 2 visit may be associated with the fact that all duloxetine patients were on the 30&#x000a0;mg dose. It was only after the week 2 visit that duloxetine could be increased to 60&#x000a0;mg. Patients treated with duloxetine also demonstrated superior improvement over placebo-treated patients in each of the disease-specific secondary measures, as well as in global functioning, quality of life, and the patients' impression of feeling better. Duloxetine-treated patients were significantly more likely to meet treatment response and remission criteria and to experience sustained improvement during acute therapy.</p><p>The results presented here extend the findings of a <italic>post hoc</italic> age subgroup analysis of four placebo-controlled trials of duloxetine in patients with GAD. In that analysis, <xref rid="b11" ref-type="bibr">Davidson <italic>et al</italic>. (2008)</xref> reported significance between treatment group improvement in older patients (&#x02265;65&#x000a0;years of age) treated with duloxetine (<italic>n</italic>&#x000a0;=&#x000a0;45) <italic>versus</italic> placebo (<italic>n</italic>&#x000a0;=&#x000a0;28) on the HAM-A total, HAM-A psychic anxiety factor, and HADS anxiety but not the HAM-A somatic anxiety factor. They also reported no significant between-treatment differences in the CGI-I or the Patient Global Impression of Improvement scores, response, or remission rates, which they attributed to the small sample size.</p><p>The success of the current study may be attributed in part to initiating duloxetine treatment with the 30&#x000a0;mg dose for 2&#x000a0;weeks. Previous GAD studies started with 30&#x000a0;mg for 1&#x000a0;week (<xref rid="b20" ref-type="bibr">Hartford <italic>et al</italic>., 2007</xref>; Nicolini <italic>et al</italic>., 2009) or 60&#x000a0;mg with a dose reduction to 30&#x000a0;mg for 2&#x000a0;weeks if 60&#x000a0;mg was not well tolerated initially (<xref rid="b23" ref-type="bibr">Koponen <italic>et al</italic>., 2007</xref>; <xref rid="b38" ref-type="bibr">Rynn <italic>et al</italic>., 2008</xref>). The slower rate of duloxetine dose titration in the current study may have contributed to the higher completion rate and lower discontinuation rates because of adverse events. Completion rates for duloxetine-treated patients in previous GAD studies ranged from 54.3% (<xref rid="b20" ref-type="bibr">Hartford <italic>et al</italic>., 2007</xref>) to 69% (Nicolini <italic>et al</italic>., 2009), and discontinuation because of adverse events ranged from 11.3% (<xref rid="b23" ref-type="bibr">Koponen <italic>et al</italic>., 2007</xref>) to 20.2% (<xref rid="b38" ref-type="bibr">Rynn <italic>et al</italic>., 2008</xref>). The <italic>post hoc</italic> age subgroup analysis of these four studies reported a 66.7% completion rate and discontinuation because of an adverse event rate of 22.2% for the older patients treated with duloxetine (<xref rid="b11" ref-type="bibr">Davidson <italic>et al</italic>., 2008</xref>).</p><p>In the current study, 60.3% of duloxetine-treated patients experienced TEAE, which was less than that reported in the previous GAD studies that were as high as 83.3% (<xref rid="b38" ref-type="bibr">Rynn <italic>et al</italic>., 2008</xref>). TEAEs that occurred at 5% and twice the rate of placebo in the current study were fewer in number and with less frequency than in the previous GAD studies, and only one TEAE (dry mouth) occurred significantly more frequently in duloxetine-treated patients. Overall, the tolerability and safety findings in this older adult patient population were consistent with previous GAD studies in mostly young adults who were &#x0003c;65&#x000a0;years of age.</p><p>There are two other studies of duloxetine in older patients, both of which were for major depressive disorder. One study (<xref rid="b34" ref-type="bibr">Raskin <italic>et al</italic>., 2007</xref>) demonstrated significant improvement in cognition and depressive symptoms with duloxetine 60&#x000a0;mg/day as compared with placebo during 8&#x000a0;weeks of treatment. The other study (<xref rid="b37" ref-type="bibr">Robinson <italic>et al</italic>., 2014</xref>) did not meet the primary outcome of significant improvement in depression as assessed by the Maier subscale (<xref rid="b28" ref-type="bibr">Maier and Philipp, 1985</xref>) of the Hamilton Depression Rating Scale (<xref rid="b19" ref-type="bibr">Hamilton, 1960</xref>) even though 65.6% of patients treated with duloxetine achieved remission during the 12-week period. Both of these studies had high completion rates with duloxetine treatment (78.3% in <xref rid="b34" ref-type="bibr">Raskin <italic>et al</italic>., 2007</xref> and 71.9% in <xref rid="b37" ref-type="bibr">Robinson <italic>et al</italic>., 2014</xref>), and rates of discontinuation because of adverse events in the duloxetine arms were relatively low (9.7% and 11.6%, respectively). TEAEs &#x02265;5% and twice the rate of placebo occurring significantly more frequently for duloxetine included dry mouth, nausea, and diarrhea in one study and dry mouth, constipation, and diarrhea in the other study.</p><p>A major strength of this study was that patient demographics were comparable with epidemiological studies in elderly GAD, which also reported a greater preponderance of women and a high frequency of comorbid medical conditions (<xref rid="b27" ref-type="bibr">Mackenzie <italic>et al</italic>., 2011</xref>). An additional strength was that both clinician-rated and patient-rated measures of anxiety were used to assess disease severity, and there was good concordance between the outcomes. However, this study was limited by its short duration of 10&#x000a0;weeks, and GAD is a chronic illness, which limits the results regarding long-term efficacy and safety. Because common psychiatric comorbidities, such as major depression, were exclusions in this study, the results may not extend to all patients who are &#x02265;65&#x000a0;years of age. In addition, the flexible-dose design did not allow definitive comparisons of duloxetine doses, because escalation was based on both efficacy and tolerability.</p><p>The results from this study demonstrated that duloxetine treatment was efficacious in the improvement of illness severity, functioning, and enjoyment of life for older adult patients with GAD. The safety profile for these older duloxetine-treated patients was consistent with previous GAD studies.</p></sec></body><back><ack><p>Our thanks to the patients who agreed to participate in this clinical trial and the investigators from the following countries: <italic>Argentina</italic>: S. M. Diamanti, C. M. Lupo, F. D. Medina, G. Noriega, and E. Serfaty; <italic>Austria</italic>: M. Schmitz, G. Schoenbeck, and A. Whitworth; <italic>Canada</italic>: L. Beauclair, R. Chandrasena, A. Fallu, P. Latimer, and A. Munshi; <italic>Germany</italic>: B. Dorn, H. J. Gertz, F. Kuhn, T. Lauter, J. Peltz, and H. P. Volz; <italic>Mexico</italic>: S. Aguilar, J. B. Corral Garcia, S. Lozano, G. Martinez, and S. Reyes; <italic>Poland</italic>: L. Bidzan, P. Bogacki, B. Janczewska, M. Perucki, J. Laczkowski, and J. Strzelec; <italic>Spain</italic>: J. R. Domenech Bisen, and A. Montejo Gonzalez; the <italic>UK</italic>: M. Blagden, B. Bodalia, and G. Chapman; and the <italic>USA</italic>: O. Caro, M. DiBuono, C. Ericksen, D. Gruener, A. Jonas, W. Julio, A. Khan, J. McDonough, A. Patel, J. Strawn, H. Thomas, and H. Hafez. This work was supported by Eli Lilly and Company, Indianapolis, IN, USA.</p></ack><sec><title>Conflict of interest</title><p>None declared.</p></sec><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Detke</surname><given-names>M</given-names></name></person-group><article-title>A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder</article-title><source>J Psychopharmacol</source><year>2008</year><volume>22</volume><issue>4</issue><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">18635722</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Hackett</surname><given-names>D</given-names></name><name><surname>Salinas</surname><given-names>E</given-names></name></person-group><article-title>Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study</article-title><source>Br J Psychiatry</source><year>2001</year><volume>179</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11435263</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Florea</surname><given-names>I</given-names></name><name><surname>Huusom</surname><given-names>AK</given-names></name></person-group><article-title>Prevention of relapse in generalized anxiety disorder by escitalopram treatment</article-title><source>Int J Neuropsychopharmacol</source><year>2006</year><volume>9</volume><issue>5</issue><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">16316482</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="book"><collab>American Psychiatric Association</collab><source>Diagnostic and Statistical Manual of Mental Disorders</source><year>1994</year><edition>4th edn</edition><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>DS</given-names></name><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Bandelow</surname><given-names>B</given-names></name><name><surname>Ferre</surname><given-names>F</given-names></name><name><surname>Pallanti</surname><given-names>S</given-names></name></person-group><article-title>An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder</article-title><source>World J Biol Psychiatry</source><year>2012</year><volume>13</volume><issue>7</issue><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">22059936</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandelow</surname><given-names>B</given-names></name><name><surname>Sher</surname><given-names>L</given-names></name><name><surname>Bunevicius</surname><given-names>R</given-names></name></person-group><article-title>Guidelines for the pharmacological treatment of anxiety disorders, obsessive&#x02013;compulsive disorder and posttraumatic stress disorder in primary care</article-title><source>Int J Psychiatry Clin Pract</source><year>2012</year><volume>16</volume><issue>2</issue><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22540422</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byers</surname><given-names>AL</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Covinsky</surname><given-names>KE</given-names></name><name><surname>Friedman</surname><given-names>MB</given-names></name><name><surname>Bruce</surname><given-names>ML</given-names></name></person-group><article-title>High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><issue>5</issue><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">20439830</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Ryan</surname><given-names>KM</given-names></name></person-group><article-title>Pain assessment: global use of the Brief Pain Inventory</article-title><source>Ann Acad Med Singapore</source><year>1994</year><volume>23</volume><issue>2</issue><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">8080219</pub-id></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>JR</given-names></name><name><surname>Dupont</surname><given-names>RK</given-names></name><name><surname>Hedges</surname><given-names>D</given-names></name><name><surname>Haskins</surname><given-names>JT</given-names></name></person-group><article-title>Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder</article-title><source>J Clin Psychiatry</source><year>1999</year><volume>60</volume><issue>8</issue><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">10485635</pub-id></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>JR</given-names></name><name><surname>Bose</surname><given-names>A</given-names></name><name><surname>Korotzer</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name></person-group><article-title>Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study</article-title><source>Depress Anxiety</source><year>2004</year><volume>19</volume><issue>4</issue><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">15274172</pub-id></element-citation></ref><ref id="b11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Pollack</surname><given-names>MH</given-names></name></person-group><article-title>Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies</article-title><source>Hum Psychopharmacol</source><year>2008</year><volume>23</volume><issue>6</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">18478624</pub-id></element-citation></ref><ref id="b12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>AC</given-names></name><name><surname>Pollack</surname><given-names>MH</given-names></name></person-group><article-title>Establishment of remission criteria for anxiety disorders</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">14658990</pub-id></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Nee</surname><given-names>J</given-names></name><name><surname>Harrison</surname><given-names>W</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure</article-title><source>Psychopharmacol Bull</source><year>1993</year><volume>29</volume><issue>2</issue><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">8290681</pub-id></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>&#x0201c;Mini-mental state&#x0201d;. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><issue>3</issue><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelenberg</surname><given-names>AJ</given-names></name><name><surname>Lydiard</surname><given-names>RB</given-names></name><name><surname>Rudolph</surname><given-names>R</given-names></name></person-group><article-title>Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>23</issue><fpage>3082</fpage><lpage>3088</lpage><pub-id pub-id-type="pmid">10865302</pub-id></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>DC</given-names></name><name><surname>Byrne</surname><given-names>GJ</given-names></name></person-group><article-title>Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis</article-title><source>J Anxiety Disord</source><year>2012</year><volume>26</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21907538</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>ECDEU Assessment Manual for Psychopharmacology</source><year>1976</year><publisher-loc>Rockville, MD</publisher-loc><publisher-name>National Institute of Mental Health (NIMH), Psychopharmacology Research Branch</publisher-name></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>The assessment of anxiety states by rating</article-title><source>Br J Med Psychol</source><year>1959</year><volume>32</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">13638508</pub-id></element-citation></ref><ref id="b19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>A rating scale for depression</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1960</year><volume>23</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14399272</pub-id></element-citation></ref><ref id="b20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartford</surname><given-names>J</given-names></name><name><surname>Kornstein</surname><given-names>S</given-names></name><name><surname>Liebowitz</surname><given-names>M</given-names></name></person-group><article-title>Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial</article-title><source>Int Clin Psychopharmacol</source><year>2007</year><volume>22</volume><issue>3</issue><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">17414743</pub-id></element-citation></ref><ref id="b21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>EJ</given-names></name><name><surname>Mathew</surname><given-names>SJ</given-names></name></person-group><article-title>Anxiety disorders: a comprehensive review of pharmacotherapies</article-title><source>Mt Sinai J Med</source><year>2008</year><volume>75</volume><issue>3</issue><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">18704983</pub-id></element-citation></ref><ref id="b22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>IR</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names><suffix>3rd</suffix></name><name><surname>Alexopoulos</surname><given-names>GS</given-names></name><name><surname>Hackett</surname><given-names>D</given-names></name></person-group><article-title>Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials</article-title><source>J Am Geriatric Soc</source><year>2002</year><volume>50</volume><issue>1</issue><fpage>18</fpage><lpage>25</lpage></element-citation></ref><ref id="b23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koponen</surname><given-names>H</given-names></name><name><surname>Allgulander</surname><given-names>C</given-names></name><name><surname>Erickson</surname><given-names>J</given-names></name></person-group><article-title>Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians</article-title><source>Prim Care Companion J Clin Psychiatry</source><year>2007</year><volume>9</volume><issue>2</issue><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">17607331</pub-id></element-citation></ref><ref id="b24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Roux</surname><given-names>H</given-names></name><name><surname>Gatz</surname><given-names>M</given-names></name><name><surname>Wetherell</surname><given-names>JL</given-names></name></person-group><article-title>Age at onset of generalized anxiety disorder in older adults</article-title><source>Am J Geriatr Psychiatry</source><year>2005</year><volume>13</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15653937</pub-id></element-citation></ref><ref id="b25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenze</surname><given-names>EJ</given-names></name><name><surname>Rollman</surname><given-names>BL</given-names></name><name><surname>Shear</surname><given-names>MK</given-names></name></person-group><article-title>Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>301</volume><issue>3</issue><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">19155456</pub-id></element-citation></ref><ref id="b26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipman</surname><given-names>RS</given-names></name></person-group><article-title>Differentiating anxiety and depression in anxiety disorders: use of rating scales</article-title><source>Psychopharmacol Bull</source><year>1982</year><volume>18</volume><issue>4</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">7156301</pub-id></element-citation></ref><ref id="b27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>CS</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Chou</surname><given-names>KL</given-names></name><name><surname>Pagura</surname><given-names>J</given-names></name><name><surname>Sareen</surname><given-names>J</given-names></name></person-group><article-title>Prevalence and correlates of generalized anxiety disorder in a national sample of older adults</article-title><source>Am J Geriatr Psychiatry</source><year>2011</year><volume>19</volume><issue>4</issue><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">21427639</pub-id></element-citation></ref><ref id="b28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Philipp</surname><given-names>M</given-names></name></person-group><article-title>Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale</article-title><source>Pharmacopsychiatry</source><year>1985</year><volume>18</volume><fpage>114</fpage><lpage>115</lpage></element-citation></ref><ref id="b29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Tobias</surname><given-names>K</given-names></name><name><surname>Zornberg</surname><given-names>GL</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Pande</surname><given-names>AC</given-names></name></person-group><article-title>Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine</article-title><source>J Clin Psychiatry</source><year>2006</year><volume>67</volume><issue>5</issue><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">16841627</pub-id></element-citation></ref><ref id="b30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolini</surname><given-names>H</given-names></name><name><surname>Bakish</surname><given-names>D</given-names></name><name><surname>Duenas</surname><given-names>H</given-names></name></person-group><article-title>Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial</article-title><source>Psychol Med</source><year>2009</year><volume>39</volume><issue>2</issue><fpage>267</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">18485261</pub-id></element-citation></ref><ref id="b31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>MH</given-names></name><name><surname>Zaninelli</surname><given-names>R</given-names></name><name><surname>Goddard</surname><given-names>A</given-names></name></person-group><article-title>Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial</article-title><source>J Clin Psychiatry</source><year>2001</year><volume>62</volume><issue>5</issue><fpage>350</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">11411817</pub-id></element-citation></ref><ref id="b32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Stanley</surname><given-names>B</given-names></name></person-group><article-title>The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults</article-title><source>Am J Psychiatry</source><year>2011</year><volume>168</volume><issue>12</issue><fpage>1266</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">22193671</pub-id></element-citation></ref><ref id="b33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskin</surname><given-names>A</given-names></name><name><surname>Schulterbrandt</surname><given-names>J</given-names></name><name><surname>Reatig</surname><given-names>N</given-names></name><name><surname>McKeon</surname><given-names>JJ</given-names></name></person-group><article-title>Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives</article-title><source>J Nerv Ment Dis</source><year>1969</year><volume>148</volume><issue>1</issue><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">5768895</pub-id></element-citation></ref><ref id="b34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskin</surname><given-names>J</given-names></name><name><surname>Wiltse</surname><given-names>CG</given-names></name><name><surname>Siegal</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><issue>6</issue><fpage>900</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">17541049</pub-id></element-citation></ref><ref id="b35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickels</surname><given-names>K</given-names></name><name><surname>Pollack</surname><given-names>MH</given-names></name><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Haskins</surname><given-names>JT</given-names></name></person-group><article-title>Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder</article-title><source>Am J Psychiatry</source><year>2000</year><volume>157</volume><issue>6</issue><fpage>968</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">10831478</pub-id></element-citation></ref><ref id="b36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickels</surname><given-names>K</given-names></name><name><surname>Zaninelli</surname><given-names>R</given-names></name><name><surname>McCafferty</surname><given-names>J</given-names></name></person-group><article-title>Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study</article-title><source>Am J Psychiatry</source><year>2003</year><volume>160</volume><issue>4</issue><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">12668365</pub-id></element-citation></ref><ref id="b37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MJ</given-names></name><name><surname>Oakes</surname><given-names>TM</given-names></name><name><surname>Raskin</surname><given-names>J</given-names></name></person-group><article-title>Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo</article-title><source>Am J Geriatr Psychiatry</source><year>2014</year><volume>22</volume><issue>1</issue><fpage>34</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">24314888</pub-id></element-citation></ref><ref id="b38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rynn</surname><given-names>M</given-names></name><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Erickson</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial</article-title><source>Depress Anxiety</source><year>2008</year><volume>25</volume><issue>3</issue><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">17311303</pub-id></element-citation></ref><ref id="b39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shear</surname><given-names>MK</given-names></name><name><surname>Vander Bilt</surname><given-names>J</given-names></name><name><surname>Rucci</surname><given-names>P</given-names></name></person-group><article-title>Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A)</article-title><source>Depress Anxiety</source><year>2001</year><volume>13</volume><issue>4</issue><fpage>166</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11413563</pub-id></element-citation></ref><ref id="b40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Harnett-Sheehan</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>BA</given-names></name></person-group><article-title>The measurement of disability</article-title><source>Int Clin Psychopharmacol</source><year>1996</year><volume>11</volume><issue>Suppl 3</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">8923116</pub-id></element-citation></ref><ref id="b41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Sheehan</surname><given-names>KH</given-names></name></person-group><article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title><source>J Clin Psychiatry</source><year>1998</year><volume>59</volume><issue>Suppl 20</issue><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9881538</pub-id></element-citation></ref><ref id="b42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Nordera</surname><given-names>G</given-names></name><name><surname>Jonkinen</surname><given-names>RH</given-names></name></person-group><article-title>Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><issue>3</issue><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">12716265</pub-id></element-citation></ref><ref id="b43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittchen</surname><given-names>HU</given-names></name><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Beesdo</surname><given-names>K</given-names></name></person-group><article-title>Generalized anxiety and depression in primary care: prevalence, recognition, and management</article-title><source>J Clin Psychiatry</source><year>2002</year><volume>63</volume><issue>Suppl 8</issue><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12044105</pub-id></element-citation></ref><ref id="b44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittchen</surname><given-names>HU</given-names></name><name><surname>Jacobi</surname><given-names>F</given-names></name><name><surname>Rehm</surname><given-names>J</given-names></name></person-group><article-title>The size and burden of mental disorders and other disorders of the brain in Europe 2010</article-title><source>Eur Neuropsychopharmacol</source><year>2011</year><volume>21</volume><issue>9</issue><fpage>655</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">21896369</pub-id></element-citation></ref><ref id="b45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><issue>6</issue><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref></ref-list></back></article>